| [604] | 1 | English French Notes Complete/Exclude
|
|---|
| 2 | GRADE/DIFFERENTIATION must be: 2 (Grade II)
|
|---|
| 3 | GRADE/DIFFERENTIATION must be: 4 (Grade IV)
|
|---|
| 4 | GRADE/DIFFERENTIATION =
|
|---|
| 5 | HISTOLOGY must be leukemia or lymphoma (9590-9948)
|
|---|
| 6 | No TNM classification is available for LYMPHOMA
|
|---|
| 7 | SUMMARY STAGE cannot be blank
|
|---|
| 8 | No TNM classification is available for KAPOSI'S SAROMA
|
|---|
| 9 | EXTENSION may not be 00 (In situ)
|
|---|
| 10 | ICDO-TOPOGRAPHY =
|
|---|
| 11 | PATHOLGIC EXTENSION =
|
|---|
| 12 | PATHOLOGIC EXTENSION may only be coded for PROSTATE (C61.9) cases
|
|---|
| 13 | REGIONAL NODES POSITIVE =
|
|---|
| 14 | LYMPH NODES may not be 0 (No lymph nodes)
|
|---|
| 15 | REGIONAL NODES EXAMINED = 99 (
|
|---|
| 16 | REGIONAL NODES POSITIVE must be 99 (Unk if nodes + or -, NA)
|
|---|
| 17 | HORMONE THERAPY =
|
|---|
| 18 | Only BREAST and PROSTATE cases may be coded as receiving
|
|---|
| 19 | endocrine surgery or endocrine radiation
|
|---|
| 20 | Dead
|
|---|
| 21 | STATUS =
|
|---|
| 22 | PLACE OF DEATH may not be blank
|
|---|
| 23 | CAUSE OF DEATH and STATE DEATH CERT may not both be blank
|
|---|
| 24 | White
|
|---|
| 25 | RACE 1 =
|
|---|
| 26 | RACE 2 =
|
|---|
| 27 | RACE 3 =
|
|---|
| 28 | RACE 4 =
|
|---|
| 29 | RACE 5 =
|
|---|
| 30 | For race combinations RACE 1 may not be 'White'
|
|---|
| 31 | A specific race code may not occur more than once
|
|---|
| 32 | ONC*2.11*15
|
|---|
| 33 | Please install ONC*2.11*15 first. Installation Halted.
|
|---|
| 34 | ONC*2.11*20
|
|---|
| 35 | ONCO*2.11*20
|
|---|
| 36 | Please install ONC*2.11*20 first. Installation Halted.
|
|---|
| 37 | The Accession Year is not 2001.
|
|---|
| 38 | GI stromal sarcomas (8936) are being collected via paper data form.
|
|---|
| 39 | The Behavior Code is not 3 (Malignant).
|
|---|
| 40 | Invalid Histology code.
|
|---|
| 41 | Select section
|
|---|
| 42 | 2001 Patient Care Evaluation Study of Gastric Cancers
|
|---|
| 43 | PATIENT INFORMATION
|
|---|
| 44 | 1400.6 1. CO-MORBID CONDITIONS (YES/NO).
|
|---|
| 45 | 1571 CO-MORBID CONDITION #1.......
|
|---|
| 46 | 1571.1 CO-MORBID CONDITION #2.......
|
|---|
| 47 | 1571.2 CO-MORBID CONDITION #3.......
|
|---|
| 48 | 1571.3 CO-MORBID CONDITION #4.......
|
|---|
| 49 | 1571.4 CO-MORBID CONDITION #5.......
|
|---|
| 50 | 1571.5 CO-MORBID CONDITION #6.......
|
|---|
| 51 | 1500 2. PRIOR EXPOSURE TO RADIATION...
|
|---|
| 52 | 1501 3. ALCOHOL CONSUMPTION...........
|
|---|
| 53 | 1572 4. DURATION OF TOBACCO USE.......
|
|---|
| 54 | 5. MENOPAUSAL STATUS AND HORMONE
|
|---|
| 55 | REPLACEMENT THERAPY..........: NA, male patient
|
|---|
| 56 | 1502 5. MENOPAUSAL STATUS AND HORMONE REPLACEMENT THERAPY..........
|
|---|
| 57 | 1503 6. H2 BLOCKER/PROTON PUMP INHIBITOR USE................
|
|---|
| 58 | 1504 7. FAMILY HISTORY OF GASTRIC CANCER.......................
|
|---|
| 59 | 1573 8. PERSONAL HISTORY OF OTHER INVASIVE MALIGNANCIES PRIOR TO THIS CANCER DIAGNOSIS....//^S X=PHDEF
|
|---|
| 60 | 9. ASSOCIATED BENIGN CONDTIONS:
|
|---|
| 61 | 1505 H-PYLORI INFECTION...........
|
|---|
| 62 | 1506 DUODENAL ULCER...............
|
|---|
| 63 | 1507 GASTRIC ULCER................
|
|---|
| 64 | 1509 PERNICIOUS ANEMIA............
|
|---|
| 65 | 1510 POLYPS OF STOMACH............
|
|---|
| 66 | 1511 POLYPOSIS OF SMALL OR LARGE BOWEL.......................
|
|---|
| 67 | 1513 ATROPHIC GASTRITIS...........
|
|---|
| 68 | 1514 GASTRIC METAPLASIA...........
|
|---|
| 69 | 10. H-PYLORI DRUGS GIVEN:
|
|---|
| 70 | 1516 PROTON PUMP INHIBITORS.......
|
|---|
| 71 | 1518 BISMUTH COMPOUNDS............
|
|---|
| 72 | 1519 11. PRIOR INTRA-ABDOMINAL SURGERY.
|
|---|
| 73 | 1520 12. YEAR OF PRIOR GASTRIC RESECTION....................
|
|---|
| 74 | CO-MORBID CONDITIONS (YES/NO) equals
|
|---|
| 75 | CO-MORBID CONDITION #1 may not be blank
|
|---|
| 76 | CO-MORBID CONDITION #1.......: 000.00 No co-morbidities
|
|---|
| 77 | CO-MORBID CONDITION #2.......:
|
|---|
| 78 | CO-MORBID CONDITION #3.......:
|
|---|
| 79 | CO-MORBID CONDITION #4.......:
|
|---|
| 80 | CO-MORBID CONDITION #5.......:
|
|---|
| 81 | CO-MORBID CONDITION #6.......:
|
|---|
| 82 | ANTIBIOTICS..................: H-pylori not present
|
|---|
| 83 | PROTON PUMP INHIBITORS.......: H-pylori not present
|
|---|
| 84 | H2 BLOCKERS..................: H-pylori not present
|
|---|
| 85 | BISMUTH COMPOUNDS............: H-pylori not present
|
|---|
| 86 | TUMOR INDENTIFICATION AND DIAGNOSIS
|
|---|
| 87 | 1521 13. PERFORMANCE STATUS AT INITIAL DIAGNOSIS....................
|
|---|
| 88 | 14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
|
|---|
| 89 | 1523 FEVER/NIGHT SWEATS...........
|
|---|
| 90 | 1524 ACUTE HEMATEMESIS............
|
|---|
| 91 | 1525 TRANSFUSIONS FOR BLOOD LOSS..
|
|---|
| 92 | 1574 WEIGHT LOSS..................
|
|---|
| 93 | 1528 EARLY SATIETY................
|
|---|
| 94 | 15. INITIAL STAGING STUDIES:
|
|---|
| 95 | 1529 CT SCAN OF ABDOMEN...........
|
|---|
| 96 | 1530 CT SCAN OF CHEST.............
|
|---|
| 97 | 1531 CT PELVIS....................
|
|---|
| 98 | 1533 GALLIUM SCAN.................
|
|---|
| 99 | 1534 BIPEDAL LYMPHANGIOGRAM (LAG).
|
|---|
| 100 | 1536 PET SCAN.....................
|
|---|
| 101 | 1538 EUS (ENDOSCOPIC ULTRASOUND)..
|
|---|
| 102 | 1539 PERITONEAL LAVAGE............
|
|---|
| 103 | 16. LABORATORY STUDIES:
|
|---|
| 104 | 17. GASTROSCOPIC EXAMINATION RESULTS:
|
|---|
| 105 | 1545 CLINICAL/VISUAL EXAMINATION..
|
|---|
| 106 | 1546 18. GASTRO-ESOPHAGEAL JUNCTION (SIEWART TYPE II/III)........
|
|---|
| 107 | 19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:
|
|---|
| 108 | 1547.3 LYMPH NODES..................
|
|---|
| 109 | 1548 20. DATE OF FIRST TISSUE DIAGNOSIS
|
|---|
| 110 | 23. MOLECULAR MARKERS:
|
|---|
| 111 | 1552 24. MITOTIC RATE..................
|
|---|
| 112 | 1553 25. TUMOR NECROSIS................
|
|---|
| 113 | 26. PHENOTYPE MODALITY USED:
|
|---|
| 114 | 1554 FLOW CYTOMETRY ON FRESH TISSUE......................
|
|---|
| 115 | 1554.1 IMMUNOHISTOCHEMISTRY ON FROZEN TISSUE......................
|
|---|
| 116 | 1554.2 IMMUNOHISTOCHEMISTRY ON PARAFIN EMBEDDED TISSUE.....
|
|---|
| 117 | 1554.3 MOLECULAR GENETICS...........
|
|---|
| 118 | 1554.4 POLYMERASE CHAIN REACTION TECHNIQUE..................
|
|---|
| 119 | 1554.5 SOUTHERN BLOT TECHNIQUE......
|
|---|
| 120 | 1555 27. ANN ARBOR STAGING.............
|
|---|
| 121 | 18. GASTRO-ESOPHAGEAL JUNCTION (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)
|
|---|
| 122 | 21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)
|
|---|
| 123 | 22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)
|
|---|
| 124 | 24. MITOTIC RATE..................: NA (not leimyosarcoma)
|
|---|
| 125 | 25. TUMOR NECROSIS................: NA (not leimyosarcoma)
|
|---|
| 126 | FLOW CYTOMETRY ON FRESH TISSUE......................: NA (not lymphoma)
|
|---|
| 127 | IMMUNOCHEMISTRY ON FROZEN TISSUE......................: NA (not lymphoma)
|
|---|
| 128 | IMMUNOHISTOCHEMISTRY ON PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)
|
|---|
| 129 | MOLECULAR GENETICS...........: NA (not lymphoma)
|
|---|
| 130 | POLYMERASE CHAIN REACTION TECHNIQUE...................: NA (not lymphoma)
|
|---|
| 131 | SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)
|
|---|
| 132 | 27. ANN ARBOR STAGING.............: NA (not lymphoma)
|
|---|
| 133 | FIRST COURSE OF TREATMENT - SURGERY
|
|---|
| 134 | 1556 28. ADHERENCE OF RESECTED PRIMARY SPECIMEN.....................
|
|---|
| 135 | 1557 29. MARGIN STATUS OF RESECTED PRIMARY SPECIMEN.............
|
|---|
| 136 | 30. EXTENT OF FREE MARGIN:
|
|---|
| 137 | 1558 PROXIMAL MARGIN..............
|
|---|
| 138 | 1558.1 DISTAL MARGIN................
|
|---|
| 139 | 31. RESECTION BEYOND STOMACH:
|
|---|
| 140 | 1559.1 TRANVERSE COLON..............
|
|---|
| 141 | 1559.5 ABDOMINAL WALL...............
|
|---|
| 142 | 1559.6 ADRENAL GLAND................
|
|---|
| 143 | 1559.8 SMALL INTESTINE..............
|
|---|
| 144 | 1560 PERIGASTRIC LYMPH NODES......
|
|---|
| 145 | 1560.1 COMMON HEPATIC LYMPH NODES...
|
|---|
| 146 | 1560.2 CELIAC LYMPH NODES...........
|
|---|
| 147 | 1560.3 SPLENIC LYMPH NODES..........
|
|---|
| 148 | 1560.4 OTHER INTRA-ABDOMINAL NODES..
|
|---|
| 149 | 1561 32. GROSSLY INVOLVED REGIONAL LYMPH NODES..................
|
|---|
| 150 | 1562 33. HCT (HEMATOCRIT) VALUES BEFORE TRANSFUSION..................
|
|---|
| 151 | 1563 34. TOTAL OPERATIVE BLOOD REPLACEMENT..................
|
|---|
| 152 | 1564 35. INTRA/PERI-OPERATIVE DEATH....
|
|---|
| 153 | 36. COMPLICATIONS REQUIRING RE-OPERATION:
|
|---|
| 154 | 1565 ANASTOMOTIC LEAK.............
|
|---|
| 155 | 1565.1 STUMP LEAK...................
|
|---|
| 156 | 1565.3 WOUND INFECTION..............
|
|---|
| 157 | 1565.6 DEAD BOWEL...................
|
|---|
| 158 | 1566 37. DATE OF SURGICAL DISCHARGE....
|
|---|
| 159 | FIRST COURSE OF TREATMENT - RADIATION
|
|---|
| 160 | 442 38. REGIONAL DOSE (cGy)...........
|
|---|
| 161 | 1575 39. BOOST DOSE (cGy)..............
|
|---|
| 162 | 1567 40. INTRA-OPERATIVE RADIATION THERAPY, DOSE (cGy)..........
|
|---|
| 163 | 1568 41. CONCURRENT CHEMOTHERAPY.......
|
|---|
| 164 | FIRST COURSE OF TREATMENT - CHEMOTHERAPY
|
|---|
| 165 | 42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
|
|---|
| 166 | 1569 43. INTRAPERITONEAL CHEMOTHERAPY..
|
|---|
| 167 | 1577 44. CHEMOTHERAPEUTIC TOXICITY.....
|
|---|
| 168 | 1578 45. CHEMOTHERAPY/SURGERY SEQUENCE.
|
|---|
| 169 | FIRST COURSE OF TREATMENT - IMMUNOTHERAPY
|
|---|
| 170 | 1570 46. ADMINSTRATION OF INTERFERON...
|
|---|
| 171 | No surgery of the primary site was performed.
|
|---|
| 172 | Proceed to data item 38.
|
|---|
| 173 | No radiation therapy was administered.
|
|---|
| 174 | Code data items 38-40 to 00000.
|
|---|
| 175 | Do not answer data item 41, and proceed to data item 42.
|
|---|
| 176 | 38. REGIONAL DOSE (cGy)...........: 00000
|
|---|
| 177 | 39. BOOST DOSE (cGy)..............: Not administered
|
|---|
| 178 | 40. INTRA-OPERATIVE RADIATION
|
|---|
| 179 | THERAPY, DOSE (cGy)..........: Not administered
|
|---|
| 180 | 41. CONCURRENT CHEMOTHERAPY.......:
|
|---|
| 181 | No chemotherapy was administered.
|
|---|
| 182 | Proceed to data item 46.
|
|---|
| 183 | No immunotherapy administered.
|
|---|
| 184 | Proceed to Treatment Complications.
|
|---|
| 185 | TREATMENT COMPLICATIONS
|
|---|
| 186 | COMPLICATION #1..............: 000.00 No complications
|
|---|
| 187 | CASE REGISTRATION
|
|---|
| 188 | 81 48. INITIALS OF CASE ABSTRACTOR...
|
|---|
| 189 | 90 49. DATE CASE WAS ABSTRACTED......
|
|---|
| 190 | PATIENT INFORMATION
|
|---|
| 191 | 1. CO-MORBID CONDITIONS:
|
|---|
| 192 | CO-MORBID CONDITION #1.......: 000.00 No co-morbidities
|
|---|
| 193 | CO-MORBID CONDITION #1.......:
|
|---|
| 194 | CO-MORBID CONDITION #2.......:
|
|---|
| 195 | CO-MORBID CONDITION #3.......:
|
|---|
| 196 | CO-MORBID CONDITION #4.......:
|
|---|
| 197 | CO-MORBID CONDITION #5.......:
|
|---|
| 198 | CO-MORBID CONDITION #6.......:
|
|---|
| 199 | 2. PRIOR EXPOSURE TO RADIATION...:
|
|---|
| 200 | 3. ALCOHOL CONSUMPTION...........:
|
|---|
| 201 | 4. DURATION OF TOBACCO USE.......:
|
|---|
| 202 | 5. MENOPAUSAL STATUS AND HORMONE
|
|---|
| 203 | REPLACEMENT THERAPY..........:
|
|---|
| 204 | 6. H2/BLOCKER PROTON PUMP
|
|---|
| 205 | 7. FAMILY HISTORY OF GASTRIC
|
|---|
| 206 | 8. PERSONAL HISTORY OF OTHER
|
|---|
| 207 | INVASIVE MALIGNANCIES PRIOR
|
|---|
| 208 | TO THIS CANCER DIAGNOSIS....:
|
|---|
| 209 | 9. ASSOCIATED BENIGN CONDITIONS:
|
|---|
| 210 | H-PYLORI INECTION............:
|
|---|
| 211 | DUODENAL ULCER...............:
|
|---|
| 212 | GASTRIC ULCER................:
|
|---|
| 213 | PERNICIOUS ANEMIA............:
|
|---|
| 214 | POLYPS OF STOMACH............:
|
|---|
| 215 | POLYPOSIS OF SMALL OR LARGE
|
|---|
| 216 | ATROPHIC GASTRITIS...........:
|
|---|
| 217 | GASTRIC METAPLASIA...........:
|
|---|
| 218 | 10. H-PYLORI DRUGS GIVEN:
|
|---|
| 219 | PROTON PUMP INHIBITORS.......:
|
|---|
| 220 | BISMUTH COMPOUNDS............:
|
|---|
| 221 | 11. PRIOR INTRA-ABDOMINAL SURGERY.:
|
|---|
| 222 | 12. YEAR OF PRIOR GASTRIC
|
|---|
| 223 | Print Gastric Cancers PCE
|
|---|
| 224 | TUMOR IDENTIFICATION AND DIAGNOSIS
|
|---|
| 225 | 13. PERFORMANCE STATUS AT INITIAL
|
|---|
| 226 | 14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
|
|---|
| 227 | FEVER/NIGHT SWEATS...........:
|
|---|
| 228 | ACUTE HEMATEMESIS............:
|
|---|
| 229 | TRANSFUSIONS FOR BLOOD LOSS..:
|
|---|
| 230 | WEIGHT LOSS..................:
|
|---|
| 231 | EARLY SATIETY................:
|
|---|
| 232 | 15. INITIAL STAGING STUDIES:
|
|---|
| 233 | CT SCAN OF ABDOMEN...........:
|
|---|
| 234 | CT SCAN OF CHEST.............:
|
|---|
| 235 | CT PELVIS....................:
|
|---|
| 236 | GALLIUM SCAN.................:
|
|---|
| 237 | BIPEDAL LYMPHANGIOGRAM (LAG).:
|
|---|
| 238 | PET SCAN.....................:
|
|---|
| 239 | EUS (ENDOSCOPIC ULTRASOUND)..:
|
|---|
| 240 | PERITONEAL LAVAGE............:
|
|---|
| 241 | 16. LABORATORY STUDIES:
|
|---|
| 242 | 17. GASTROSCOPIC EXAMINATION RESULTS:
|
|---|
| 243 | CLINICAL/VISUAL EXAMINATION..:
|
|---|
| 244 | 18. GASTRO-ESOPHAGEAL JUNCTION
|
|---|
| 245 | (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)
|
|---|
| 246 | (SIEWART TYPE II/III)........:
|
|---|
| 247 | 19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:
|
|---|
| 248 | LYMPH NODES..................:
|
|---|
| 249 | 20. DATE OF FIRST TISSUE DIAGNOSIS:
|
|---|
| 250 | 21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)
|
|---|
| 251 | 22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)
|
|---|
| 252 | 23. MOLECULAR MARKERS:
|
|---|
| 253 | 24. MITOTIC RATE..................: NA (not leimyosarcoma)
|
|---|
| 254 | 25. TUMOR NECROSIS................: NA (not leimyosarcoma)
|
|---|
| 255 | 24. MITOTIC RATE..................:
|
|---|
| 256 | 25. TUMOR NECROSIS................:
|
|---|
| 257 | 26. PHENOTYPE MODALITY USED:
|
|---|
| 258 | FLOW CYTOMETRY ON FRESH
|
|---|
| 259 | TISSUE......................: NA (not lymphoma)
|
|---|
| 260 | IMMUNOCHEMISTRY ON FROZEN
|
|---|
| 261 | IMMUNOHISTOCHEMISTRY ON
|
|---|
| 262 | PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)
|
|---|
| 263 | MOLECULAR GENETICS...........: NA (not lymphoma)
|
|---|
| 264 | POLYMERASE CHAIN REACTION
|
|---|
| 265 | TECHNIQUE...................: NA (not lymphoma)
|
|---|
| 266 | SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)
|
|---|
| 267 | 27. ANN ARBOR STAGING.............: NA (not lymphoma)
|
|---|
| 268 | FLOW CYTOMETRY ON FRESH
|
|---|
| 269 | IMMUNOCHEMISTRY ON FROZEN
|
|---|
| 270 | IMMUNOHISTOCHEMISTRY ON
|
|---|
| 271 | PARAFIN EMBEDDED TISSUE.....:
|
|---|
| 272 | MOLECULAR GENETICS...........:
|
|---|
| 273 | POLYMERASE CHAIN REACTION
|
|---|
| 274 | SOUTHERN BLOT TECHNIQUE......:
|
|---|
| 275 | 27. ANN ARBOR STAGING..............:
|
|---|
| 276 | FIRST COURSE OF TREATMENT - SURGERY
|
|---|
| 277 | 28. ADHERENCE OF RESECTED PRIMARY
|
|---|
| 278 | 29. MARGIN STATUS OF RESECTED
|
|---|
| 279 | PRIMARY SPECIMAN.............:
|
|---|
| 280 | 30. EXTENT OF FREE MARGIN:
|
|---|
| 281 | PROXIMAL MARGIN..............:
|
|---|
| 282 | DISTAL MARGIN................:
|
|---|
| 283 | 31. RESECTION BEYOND STOMACH:
|
|---|
| 284 | TRANVERSE COLON..............:
|
|---|
| 285 | ABDOMINAL WALL...............:
|
|---|
| 286 | ADRENAL GLAND................:
|
|---|
| 287 | SMALL INTESTINE..............:
|
|---|
| 288 | PERIGASTRIC LYMPH NODES......:
|
|---|
| 289 | COMMON HEPATIC LYMPH NODES...:
|
|---|
| 290 | CELIAC LYMPH NODES...........:
|
|---|
| 291 | SPLENIC LYMPH NODES..........:
|
|---|
| 292 | OTHER INTRA-ABDOMINAL NODES..:
|
|---|
| 293 | 32. GROSSLY INVOLVED REGIONAL
|
|---|
| 294 | 33. HCT (HEMATOCRIT) VALUES BEFORE
|
|---|
| 295 | 34. TOTAL OPERATIVE BLOOD
|
|---|
| 296 | 35. INTRA/PERI-OPERATIVE DEATH....:
|
|---|
| 297 | 36. COMPLICATIONS REQUIRING RE-OPERATION:
|
|---|
| 298 | ANASTOMOTIC LEAK.............:
|
|---|
| 299 | STUMP LEAK...................:
|
|---|
| 300 | WOUND INFECTION..............:
|
|---|
| 301 | DEAD BOWEL...................:
|
|---|
| 302 | 37. DATE OF SURGICAL DISCHARGE....:
|
|---|
| 303 | #################### #################### ####################
|
|---|
| 304 | #################### #################### ####################
|
|---|
| 305 | #################### #################### ####################
|
|---|
| 306 | #################### #################### ####################
|
|---|
| 307 | #################### #################### ####################
|
|---|
